▶️Navigating China’s Multi-Level Coverage Framework: Insights from the C-List Strategy Panel
In this C-List Masterclass live strategy panel, our panelists engaged in a dynamic discussion on the evolving access landscape in China, exploring key strategic questions:
1. Why traditional affordability levers fall short in China
Why is an integrated, system-level view of access critical—not only for success in China, but for optimizing global portfolio performance?
2. Assessing pricing risk in China
What’s changing in China’s pricing environment? What should global firms consider as they reassess market potential and pricing strategy?
3. Pathway dynamics and strategic choices
- How does the final dual-list workplan depart from the original C-List proposal—and what do those changes reveal about policy direction and strategic considerations for pricing and go-to-market planning?
- NRDL vs. commercial pathways: Can commercial health insurance in China play a meaningful role in staged access strategies?
- Navigating Huiminbao delisting risks in the C-List era: practical short-term responses and long-term repositioning strategies for foreign brands
- Life cycle management and evidence strategy: how to strategically position products across NRDL and commercial pathways for long-term access optimization
Panelists:
Dr. Boxiong Tang – Former Head of HEOR at Pfizer, Janssen, and BeiGene; Chair, ISPOR Asia HTA Consortium; a leading voice in shaping China’s HTA framework.
Ed Schoonveld – Former Global Pricing Head at Wyeth, Eli Lilly, and BMS; Former Head of Value & Access Practice at ZS Associates; author of The Price of Global Health.
Kelly Ke – Award-winning former senior advisor at Deloitte US Life Sciences practice; Founder, bizi LLC; author of NRDL+, a widely followed China market access newsletter among global pharma leaders.
